Oxford-AstraZeneca COVID-19 Vaccine Resumes Phase III Clinical Trials in the UK Following Regulatory Approval

United KingdomAstraZenecaOn the 12th, a company spokesperson announced that the "Oxford COVID-19 Vaccine," jointly developed by the University of Oxford and AstraZeneca in the UK, has been approved by the UK regulatory authority and will resume.Clinical Trial。

A spokesperson for UK-based AstraZeneca stated that safety reviewers on the vaccine review committee had advised the UK Medicines and Healthcare products Regulatory Agency (MHRA) that it was safe to resume the vaccine trial. Following approval, the company has resumed the UK trial of the vaccine.Clinical Trials. The spokesperson stated that this vaccine is one of the most advanced vaccines in the world.

Meanwhile, in a statement, the University of Oxford indicated that the independent review process for the vaccine had been concluded. In accordance with recommendations from the Vaccine Review Committee and the UK Medicines and Healthcare products Regulatory Agency (MHRA), Phase III trials of the vaccine will resume at all clinical sites across China.

On September 8, the vaccine named AZD1222 was paused in its Phase III human clinical trials after a UK volunteer experienced a “seriousAdverse Reactions”, temporarily halting the vaccination trial. According to media reports, the volunteer exhibited neurological symptoms associated with rare myelitis.

Sir Jeremy Farrar, Chair of the Wellcome Trust and a member of the UK Government’s Scientific Advisory Group for Emergencies (SAGE), stated, “For me, the proper conduct of vaccine trials, the involvement of regulators with independent oversight authority, and the implementation of temporary pauses are crucial.”

UK Health Secretary Matt Hancock stated that the resumption of Phase III trials for the vaccine was reassuring and anticipated, adding, “In the best-case scenario, the vaccine could be rolled out by the end of this year. However, I believe it is more likely to happen next year, with the first few months of next year being the most probable timeframe.”